A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

I. Jung Lee, Yu Hua Lan, Ping Yi Wu, Yan Wei Wu, Yu Hung Chen, Sheng Che Tseng, Tzu Jiun Kuo, Cheng Pu Sun, Jia Tsrong Jan, Hsiu Hua Ma, Chun Che Liao, Jian Jong Liang, Hui Ying Ko, Chih Shin Chang, Wen Chun Liu, Yi An Ko, Yen Hui Chen, Zong Lin Sie, Szu I. Tsung, Yi Ling LinI. Hsuan Wang, Mi Hua Tao

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Numerous vaccines have been developed to address the current COVID-19 pandemic, but safety, cross-neutralizing efficacy, and long-term protectivity of currently approved vaccines are still important issues. In this study, we developed a subunit vaccine, ASD254, by using a nanoparticle vaccine platform to encapsulate the SARS-CoV-2 spike receptor-binding domain (RBD) protein. As compared with the aluminum-adjuvant RBD vaccine, ASD254 induced higher titers of RBD-specific antibodies and generated 10- to 30-fold more neutralizing antibodies. Mice vaccinated with ASD254 showed protective immune responses against SARS-CoV-2 challenge, with undetectable infectious viral loads and reduced typical lesions in lung. Besides, neutralizing antibodies in vaccinated mice lasted for at least one year and were effective against various SARS-CoV-2 variants of concern, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and B.1.1.529 (Omicron). Furthermore, particle size, polydispersity index, and zeta-potential of ASD254 remained stable after 8-month storage at 4°C. Thus, ASD254 is a promising nanoparticle vaccine with good immunogenicity and stability to be developed as an effective vaccine option in controlling upcoming waves of COVID-19.

Original languageEnglish
Article number2149353
JournalEmerging Microbes and Infections
Volume12
Issue number1
DOIs
StatePublished - 2023
Externally publishedYes

Keywords

  • COVID-19
  • Nanoparticle vaccine
  • SARS-CoV-2
  • cross-protectivity
  • durable antibody response
  • variants of concern

Fingerprint

Dive into the research topics of 'A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern'. Together they form a unique fingerprint.

Cite this